Skip to content
10-Q

Quarterly Report

GlobeStar Therapeutics Corp

0001161697-23-000332

← back to feed
Filed
May 31, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · May 25, 2023 787.69M sh
Cash And Equivalents Q2 2023 · Mar 31, 2023 $176
Cash And Equivalents Q2 2023 · Sep 30, 2022 $6.37K
Current Liabilities Q2 2023 · Mar 31, 2023 $1.29M
Current Liabilities Q2 2023 · Sep 30, 2022 $1.2M
Total Liabilities Q2 2023 · Mar 31, 2023 $1.29M
Total Liabilities Q2 2023 · Sep 30, 2022 $1.2M
Current Assets Q2 2023 · Mar 31, 2023 $176
Current Assets Q2 2023 · Sep 30, 2022 $9.92K
Total Assets Q2 2023 · Mar 31, 2023 $176
Total Assets Q2 2023 · Sep 30, 2022 $9.92K
Operating Cash Flow Q2 2023 · Mar 31, 2022 −$240.38K
Stockholders Equity Q2 2023 · Mar 31, 2022 −$1.08M
Stockholders Equity Q2 2023 · Dec 31, 2021 −$897.2K
Stockholders Equity Q2 2023 · Sep 30, 2021 −$725.82K
Net Income Q2 2023 · Mar 31, 2022 −$688.56K
Net Income Q2 2023 · Mar 31, 2022 −$1.02M
Net Income Q2 2023 · Dec 31, 2021 −$332.84K
Operating Income Q2 2023 · Mar 31, 2022 −$662.31K
Operating Income Q2 2023 · Mar 31, 2022 −$828.6K
Stock Issued Q2 2023 · Feb 28, 2022 6M sh